BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy
Executive Summary
- BioMark Diagnostics announced the formal grant of patents for its metabolic liquid‑biopsy platform in China (ZL 201980092723.X) and Japan (2023‑111262).
- The patented technology demonstrated >90% sensitivity for early‑stage lung cancer in a peer‑reviewed study, underscoring strong clinical performance.
- Securing IP in two of Asia’s largest healthcare markets positions BioMark to pursue licensing, partnership, and commercial expansion opportunities in rapidly growing liquid‑biopsy markets (≈ US$670 M in China and US$912 M in Japan by 2030).
Key Details
- Patents Granted:
- China – Patent No. ZL 201980092723.X covering metabolite‑based lung cancer detection.
-
Japan – Patent No. 2023‑111262 covering the same technology.
-
Clinical Performance:
-
Study published in International Journal of Molecular Sciences reports >90% sensitivity for early‑stage lung cancer using BioMark’s platform.
-
Market Opportunity Estimates:
- China liquid‑biopsy market projected to exceed US$670 million by 2030.
-
Japan liquid‑biopsy market projected to exceed US$912 million by 2030.
-
Strategic Implications (CEO Quote):
-
“Securing these patents … is a transformational milestone… strengthens our global IP estate and positions us to capture significant commercial and clinical leadership, opening up new opportunities for expansion, technology licensing, and strategic partnerships.” – Rashid Ahmed Bux, President & CEO.
-
Potential Actions:
- Pursue technology licensing agreements in China and Japan.
- Explore strategic partnerships with regional diagnostic and healthcare providers.
Notable Quotes
“Securing these patents in two of Asia's largest healthcare markets is a transformational milestone for BioMark,” said Rashid Ahmed Bux, President & CEO.
All boilerplate, forward‑looking disclaimer, and contact information have been omitted per instructions.